This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Shalby Q2 FY27: consolidated revenue up 9.7 percent, PAT up 8.4 percent, margins squeezed
SHALBY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated for the quarter ended 30 September 2026, revenue rose 9.7 percent to Rs 3,131.73 million from Rs 2,854.32 million a year earlier and profit after tax rose 8.4 percent to Rs 78.86 million from Rs 72.78 million. EBITDA margin narrowed about 1.4 points to 13.2 percent. Standalone quarter PAT was Rs 235.04 million on revenue of Rs 2,453.19 million. Two directors were appointed, subject to shareholder approval.
Revenue and profit grew, but margin compression and a wider implant manufacturing loss point to cost pressure; the stock may react cautiously.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹313.2 Cr | ₹285.4 Cr | +9.7% |
| Operating profit | ₹11.43 Cr | ₹14.60 Cr | −21.7% |
| Profit after tax | ₹7.89 Cr | ₹7.28 Cr | +8.3% |
| EBITDA margin | 13.2% | 14.6% | −1.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.